Related Experiment Videos
[Erectile dysfunction after surgery for rectosigmoid tumors--diagnosis and therapy].
Summary
Erectile dysfunction (ED) affects two-thirds of men post-rectosigmoid surgery, yet remains largely untreated. While intracavernous injections show promise, oral medications like sildenafil are less effective for this patient group.
Area of Science:
- Oncology
- Urology
- Sexual Medicine
Context:
- Radical rectosigmoid tumor resections can significantly impact male sexual function.
- Erectile dysfunction (ED) is a common, yet often underdiagnosed and undertreated, complication following these procedures.
Purpose:
- To evaluate the diagnostic and therapeutic strategies for managing ED after rectosigmoid cancer surgery.
- To assess the efficacy of current ED treatments in this specific patient population.
Summary:
- A study of 167 men undergoing rectosigmoid surgery found ED developed in 68.6% of those with pre-existing sexual activity.
- Libido and ejaculation were also frequently impaired post-surgery.
- Only 40% of men with ED received examination or treatment, with oral sildenafil showing limited efficacy and intracavernous injections being effective but underutilized.
Impact:
- Highlights the significant prevalence of ED after rectosigmoid cancer surgery.
- Underscores the need for improved screening, diagnosis, and treatment protocols for post-surgical ED.
- Suggests a potential role for intracavernous injections despite patient reluctance.